Allianz SE Acquires 1,678 Shares of Elevance Health, Inc. $ELV

Allianz SE lifted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 12.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 15,535 shares of the company’s stock after acquiring an additional 1,678 shares during the period. Allianz SE’s holdings in Elevance Health were worth $5,446,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ELV. Murphy Middleton Hinkle & Parker Inc. acquired a new stake in Elevance Health during the 4th quarter worth approximately $5,941,000. Victory Capital Management Inc. lifted its holdings in shares of Elevance Health by 31.1% in the third quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after buying an additional 109,462 shares in the last quarter. Caprock Group LLC purchased a new stake in Elevance Health in the third quarter valued at approximately $1,638,000. Bright Rock Capital Management LLC bought a new position in shares of Elevance Health in the fourth quarter worth approximately $7,362,000. Finally, Prana Capital Management LP boosted its holdings in shares of Elevance Health by 798.9% during the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock valued at $16,684,000 after buying an additional 45,889 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ELV. The Goldman Sachs Group boosted their price objective on Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Truist Financial lifted their price target on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Barclays upped their price target on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Sanford C. Bernstein increased their price objective on Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a report on Friday, April 24th. Finally, Deutsche Bank Aktiengesellschaft raised Elevance Health from a “hold” rating to a “buy” rating and raised their price target for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. Fourteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $416.11.

Insider Transactions at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.34% of the company’s stock.

Elevance Health Stock Up 1.1%

Shares of ELV stock opened at $403.74 on Friday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The firm has a market capitalization of $87.68 billion, a P/E ratio of 17.17, a PEG ratio of 2.26 and a beta of 0.67. The firm’s fifty day moving average price is $366.62 and its two-hundred day moving average price is $344.86. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the prior year, the company posted $11.97 EPS. The company’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities analysts predict that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio is currently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.